▶ Watch on YouTube
Health

FDA creates a safety council to monitor vaccines and gene therapies after approval

2026-11-19 · Nuevo Día
FDA creates a safety council to monitor vaccines and gene therapies after approval

The U.S. Food and Drug Administration (FDA) announced on Thursday the creation of the CBER Safety Council, a new body to strengthen oversight of biological products after approval, such as vaccines, cell and gene therapies and blood products. The council takes effect today, November 19.

The new body, within the Center for Biologics Evaluation and Research (CBER), will be separate from the offices that approve products and will report directly to the center's director. Its work will be to review safety signals, assess the balance of benefits and risks, and recommend measures such as labeling changes, post-market studies or even withdrawing a product from the market.

The council replaces CBER's former Safety Working Group and will coordinate with the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health, drawing on surveillance systems such as VAERS and the FDA's Sentinel program. The agency said it will publish more details on the council's structure and membership later.

Photo: Reuters

Source: FDA

← More news in Health · Leer en español